Evidence map›Paper›PMID 42483671›Full record

ReviewFrontiers in endocrinology2026

Some cases of primary hyperparathyroidism may not be truly primary in origin.

De-Ya Kong, De-Ru Kong, Bai-Qing Peng, Li-Yuan Mu, Xiao-Chun Cheng, Xi-Rui Li, Xiu-Quan Qu, Dong-Li Liu, Zhao-Hai Li, Ao-Ran Li and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

De-Ya Kong *Xiangya School of Medicine, Central South University, Changsha, China.
De-Ru Kong *The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Bai-Qing PengThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li-Yuan MuThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiao-Chun ChengThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xi-Rui LiThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiu-Quan QuThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Dong-Li LiuThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhao-Hai LiThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ao-Ran LiThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ling-Quan KongThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder and is traditionally considered to result from intrinsic pathology. However, this traditional view is challenged by several persistent clinical and epidemiological observations. Therefore, we hypothesize that some cases of PHPT may not be truly primary in origin. Some of them may be irreversible secondary hyperparathyroidism (tertiary hyperparathyroidism), which may be initiated and perpetuated by widely existed chronic calcium and/or vitamin D insufficiency. The "primary" (in fact, irreversible secondary hyperparathyroidism or "tertiary" hyperparathyroidism) and "secondary" hyperparathyroidism states are not dichotomous but are linked through a process of chronic stimulation, adaptive hyperplasia, and eventual clonal transformation. This model is supported by epidemiological evidence demonstrating an association between low lifelong calcium intake and increased PHPT risk, physiological evidence of persistent PTH suppressibility by calcium intake, and the high rate of clinical misdiagnosis between primary and secondary hyperparathyroidism. If validated, this reframing would mandate a paradigm shift in the understanding and management of PHPT or irreversible secondary hyperparathyroidism. It emphasizes the critical need to rigorously identify and correct underlying nutritional deficiency as a fundamental diagnostic and therapeutic step, transforming the management approach from a predominantly surgical model to one focused on prevention, early medical intervention, and addressing a key modifiable environmental cause.

Indexed as

Hyperparathyroidism, PrimaryHyperparathyroidism, SecondaryCalciumHumansVitamin D DeficiencyCalciumcalcium and/or vitamin D insufficiencyparathyroid hyperplasiaprimary hyperparathyroidismsecondary hyperparathyroidismtertiary hyperparathyroidismvitamin D deficiency

Identifiers

PMID42483671
PMCPMC13385567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.